Self-emulsifying drug delivery systems (SEDDS) are defined as isotropic mixtures of oils, surfactants, and co-solvents. The systems can form fine oil in water (o/w) emulsions (SEDDS) with a droplet size between 100 and 1000 nm or in microemulsions (SMEDDS) with a droplet size of less than 100 nm when meeting with aqueous media. SEDDS/ SMEDDSs may offer a new strategy for enhancing the oral bioavailability of poorly water soluble and lipophilic drugs. [1] [2] [3] [4] However, recent studies suggest that there are some shortcomings in the stability and safety of SEDDS/ SMEDDSs. First of all, SEDDS/SMEDDSs are normally in liquid or semi-solid form and are encapsulated in soft gelatin capsules with high manufacturing costs. 5) Some of the alcohol or other cosolvents in the SEDDSs possibly move into the shells of the capsule, which results in the precipitation of the drug.
Self-emulsifying drug delivery systems (SEDDS) are defined as isotropic mixtures of oils, surfactants, and co-solvents. The systems can form fine oil in water (o/w) emulsions (SEDDS) with a droplet size between 100 and 1000 nm or in microemulsions (SMEDDS) with a droplet size of less than 100 nm when meeting with aqueous media. SEDDS/ SMEDDSs may offer a new strategy for enhancing the oral bioavailability of poorly water soluble and lipophilic drugs. [1] [2] [3] [4] However, recent studies suggest that there are some shortcomings in the stability and safety of SEDDS/ SMEDDSs. First of all, SEDDS/SMEDDSs are normally in liquid or semi-solid form and are encapsulated in soft gelatin capsules with high manufacturing costs. 5) Some of the alcohol or other cosolvents in the SEDDSs possibly move into the shells of the capsule, which results in the precipitation of the drug. 1, 6) Therefore, a new SEDDS called the solid selfemulsifying drug delivery system (S-SEDDS) was prepared by incorporating a liquid self-emulsifying formulation into a solid dosage form. [5] [6] [7] [8] S-SEDDSs have the advantages of higher stability, longer storage time, lower irritation of gastrointestinal tract and lower production costs compared with conventional SEDDS. Secondly, plenty of surfactants and cosolvents are added into the formulations of SEDDS/SMEDDSs to prevent precipitation of the drug when diluted by gastrointestinal (GI) fluids. However, more surfactants may cause gastrointestinal side effects 9, 10) ; therefore, a new thermodynamically stable formulation called the supersaturatable self-emulsifying drug delivery system (sSEDDS) was designed to contain a reduced amount of surfactant and watersoluble polymers as a supersaturated promoter to prevent precipitation of the drug by generating and maintaining a supersaturated state in vivo. In comparison with conventional SEDDSs, sSEDDS formulations can result in enhanced stability and lower side effects. 10) This study combines the advantages of S-SEDDSs with those of sSEDDSs by incorporating a supersaturatable liquid self-emulsifying formulation into a solid dosage form. This can possibly overcome the disadvantages of liquid SEDDSs and the high surfactant levels in conventional SEDDS formulations described above. Although increasing studies have focused on the area of S-SEDDSs or sSEDDSs, related reports are limited. There has been no previous work that was carried out to investigate the combination of SEDDS and S-SEDDS technology with sSEDDSs. Docetaxel (DTX) is an antineoplastic agent belonging to the second generation of the taxoid family. It was identified in 1986 as an alternative to paclitaxel. It has become one of the most important chemotherapeutic agents and is widely used against ovarian carcinoma, advanced breast cancer, lung cancer, and head/neck cancer. [11] [12] [13] Docetaxel is practically insoluble in water and is often dissolved in polysorbate 80 (Tween 80). However, due to the high content of Tween 80, acute hypersensitivity reactions have been found in the majority of patients treated in the clinical trials, sometimes even leading to death. 14) To avoid and/or alleviate these side effects, some new preparations including liposomes 15) and nanoparticles 16) have been developed. Another attractive approach to overcome the drawbacks of the above intravenous dosage is to develop oral formulations that have advantages in reducing the potential toxicity and improving compli-ance. [17] [18] [19] However, preclinical studies have suggested that docetaxel was not significantly absorbed after oral administration, and the bioavailability in rats was observed to be only 1.3%, 17) and only slightly higher (8%) in humans. 18) The hepatic first-pass metabolism and the affinity of docetaxel to Pglycoprotein are the most important explanations for its poor solubility and oral bioavailability.
Amongst the various drug delivery systems, the SEDDS is considered an ideal alternative delivery method for enhancing the oral bioavailability of poorly water-soluble compounds. [1] [2] [3] [4] The objectives of the present study were therefore: (1) to develop a new solid supersaturatable SEDDS (DTX-S-sSEDDS) by combining the technology of S-SEDDS with sSEDDS to improve the solubility, dissolution and oral bioavailability of docetaxel, and (2) to determine whether the new S-sSEDDSs may have any advantages in solubility, dissolution, bioavailability, stability and safety compared with the conventional liquid SEDDSs. Table 1 .
MATERIALS AND METHODS

Chemicals and Reagents
Preparation of Conventional Liquid SEDDSs of Docetaxel (DTX-SEDDS): Labrafac, Cremophor RH40, and Transcutol P were accurately weighed in the ratio of 30 : 50 : 20 (w/w) and mixed. When the total amount of mixture reached 600 mg (or 1000 mg), 40 mg of docetaxel was dispersed into the above mixture of oil, surfactants and co-solvents. Then, the components were mixed by gentle stirring and vortexed at 37°C until the docetaxel was completely dissolved. Finally, the conventional liquid SEDDS (DTX-SEDDS 1 or DTX-SEDDS 2 ) was obtained and sealed at room temperature.
Preparation of Liquid Supersaturatable SEDDS of Docetaxel (DTX-sSEDDS): HPMC as a supersaturated promoter was dispersed into the above DTX-SEDDS 1 (or DTX-SEDDS 2 ), composing 2.5% of the total amount. Then, the supersaturatable liquid SEDDSs of docetaxel (DTXsSEDDS 1 and DTX-sSEDDS 2 ) were obtained. During the preparation of the DTX-sSEDDS, different types and quantities of HPMC were used in the formulation. Additionally, the effect of HPMC on the dissolution was also observed, according to the method described under item 'Dissolution Test in Vitro. ' Solid Supersaturatable SEDDS of Docetaxel (DTX-SsSEDDS) Prepared by Spray Drying: The prepared DTXsSEDDS 1 (approximately 6.0 g) containing 400 mg of DTX was added to 100 ml of distilled water and dissolved with lactose (8.0 g) by magnetic stirring. Likewise, the prepared DTX-sSEDDS 2 (approximately 10.0 g) containing 400 mg of DTX was added to 160 ml of distilled water and dissolved with lactose (13.0 g). The solution was kept at 50°C for 10 min to obtain a good o/w emulsion. The emulsion was spray-dried with a Büchi mini spray dryer B-191 apparatus (Büchi, Switzerland) under the following conditions: inlet temperature, 120°C; outlet temperature, 65°C; aspiration, 85%; drying air flow, 500 N l/h; feeding rate of the emulsion, 5 ml/min. Subsequently, the particles of the DTX-SsSEDDS 1 (or DTX-S-sSEDDS 2 ) were collected and sealed at room temperature. The effects of different solid water soluble carriers such as mannitol, dextran 40 and lactose on properties such as appearance, repose angle, and reconstituted emulsions of the prepared solid particles were also evaluated. Solid Supersaturatable SEDDS of Docetaxel (DTX-SsSEDDS) Prepared by Physical Adsorption: The solid supersaturatable SEDDS of Docetaxel (DTX-S-sSEDDS 3 ) was obtained by directly mixing the prepared DTX-sSEDDS 1 with lactose. Additionally, other commonly used excipients such as pregelatinized starch, microcrystalline cellulose, dextrin, mannitol and micropowder silica gel were also tested. The multiples of adsorbents, repose angles, and properties of the reconstituted emulsions of the prepared solid particles were used as evaluation indexes. The value of the multiples of adsorbent is equal to the ratio of the amount of the solid carrier and oily formulation as the repose angle of particles is near 40°.
Reconstitution Properties of Solid SMEDDS Visual Evaluation: The DTX-S-sSEDDS (115 mg) or liquid SEDDS (50 ml), described above, were dispersed by gently mixing (30 s) with 20 ml of distilled water and then incubating for 10 min at 25°C. The performance of the formulations was visually assessed according to the grading system 21) : a rapidly forming emulsion that is clear or slightly bluish in appearance was denoted by 'A'; a rapidly forming, slightly less clear emulsion that has a bluish white appearance was denoted by 'B'; a bright white emulsion was denoted by 'C'; and a slightly oily, grayish white emulsion was denoted by 'D. ' Droplet Size and Zeta Potential of Reconstituted Emulsions: The average droplet size and zeta potential of the above reconstituted emulsions from the DTX-S-sSEDDS or liquid SEDDS were assessed by photo correlation spectroscopy (Nano ZS90, Malvern Instruments, U.K.).
Morphological Analysis Morphology Observation by Transmission Electron Microscope (TEM): A drop of the above reconstituted emulsions from the DTX-S-sSEDDS 1 or liquid DTX-SEDDS 1 was pointed at the copper net and dyed by a 1% phosphomolybdate solution. The morphology of the emulsion was investigated by the transmission electron microscope (TEM, Tecnai G 2 20, FEI, Holland). Morphology Observation by Scanning Electron Microscope (SEM): The outer macroscopic structure of the solid particles of the DTX-S-sSEDDS 1 was investigated by SEM using a JSM-5610LV scanning electron microscope (JEOL, Japan). The sample was fixed on a SEM-stub using doublesided adhesive tape and then coated with a thin layer of gold.
Solid State Characterization of S-sSEDDS Differential Scanning Calorimetry (DSC): The physical state of docetaxel in the S-sSEDDS was characterized by the differential scanning calorimetry thermogram analysis (Model Pyris 1, PerkinElmer, U.S.A.). The samples include pure docetaxel, lactose, a physical mixture of docetaxel and lactose (1 : 20) and the DTX-S-sSEDDS 1 and were placed in standard aluminum pans and then scanned at a temperature ramp speed of 10°C/min between 30 to 250°C under a nitrogen gas flow of 40 ml/min.
X-Ray Powder Diffraction: To verify the physical state of docetaxel in the S-sSEDDS 1 , X-ray powder scattering measurements were carried out with a Rigaku-D/MAX-IIIA diffractometer (Rigaku Co., Ltd., Japan). The radiation was generated by a copper Ka filter, with DSϭSSϭ1°at 35 kV and 30 mA. The powder was scanned over a range of 2q values, from 3 to 50°, at the speed of 10°/min and a sampling interval of 0.02°.
Dissolution Test in Vitro Dissolution profiles were evaluated according to the method in the Ch.P-2005 (Appendix XC, the third method) in 250 ml of media at 37.0Ϯ0.5°C for 2 h, with a stirring rate of 100 rpm. Dissolution samples were collected at 15, 30, 45, 60, and 120 min, and then suitable solutions were withdrawn and equivalent amounts of media were added. Samples were filtered through a 0.45-mm membrane filter, and the concentration of DTX was analyzed by HPLC. The analysis was performed using an Agilent 1100 series HPLC and a Diamonsil C 18 (250 mmϫ4.6 mm, 5 mm) column. The mobile phase was methanol and water (76 : 24), and the flow rate was 1 ml/min. The wavelength of the UV detector was at 230 nm, and the injection volume was 20 ml. The in vitro dissolution characteristics of the DTX-SsSEDDS 1 were studied, and the effect of different drug contents given the dissolution media was considered. The dissolution of other SEDDSs with different formulations and preparation methods were also compared.
Stability Testing The DTX-S-sSEDDS 1 powder was prepared according to the item 'Solid supersaturatable SEDDS of docetaxel (DTX-S-sSEDDS) prepared by spray drying' and was mixed with 0.3% of magnesium stearate, then filled into the capsules and packed into high density plastic bottles. To assess the stability, the samples were kept at 25Ϯ2°C and 60Ϯ10% RH for observation. The appearances, content, visual evaluation and droplet size of the reconstituted emulsions and in vitro dissolution were estimated.
Absorption Study in Vivo Bioavailability Studies in Rats: Male Sprague-Dawley rats provided by the Experimental Animal Center of Wuhan University (certificate number: SCXK(E)2008-0004) weighing 200 g were used for the oral administration study. The animal experiments complied with the requirements of the National Act on the use of experimental animals (People's Republic of China). All of the rats were fasted for 12 h before the drug administration, with free access to water. The animals were divided at random into four groups and were administered the DTX-S-sSEDDS 1 , liquid DTX-SEDDS 1 , DTX powder suspension and the DTX commercial injection. The formulations of the DTX-SsSEDDS 1 , liquid DTX-SEDDS 1 and DTX powder suspension were administrated by gavage at a DTX dose of 10 mg/kg. Blood samples (0.5 ml) were collected via the caudal vein at 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0, 6.0, and 8.0 h after administration. On the other hand, the DTX commercial injection group was injected via the caudal vein at the same dose of 10 mg/kg. Blood samples (0.5 ml) were collected via the caudal vein at 0.083, 0.16, 0.25, 0.5, 1.0, 2.0, 3.0, 5.0, and 8.0 h after administration. Blood samples were placed into heparinized tubes and centrifuged at 5000 g for 10 min. The plasma samples were subsequently collected and stored at Ϫ30°C for determination.
Determination of Docetaxel in Rat Plasma by Reverse Phase (RP)-HPLC: A modified HPLC/UV method 19, 22) was applied to determine the DTX concentration in plasma. The chromatographic column used was a Hypersil ODS C18 column (250 mmϫ4.6 mm, 5 mm). The mobile phase was composed of methanol and water (65 : 35). The flow rate was 1.0 ml/min. The column temperature was set at 40°C. The column injection volume was 20 ml and the effluent was monitored at 230 nm. Paclitaxel was used as an internal standard. The plasma extraction procedure was as follows: a 100 ml plasma sample was added into an Eppendorf (EP) tube followed by 20 ml of an internal standard solution (5 mg/ml) and 20 ml of a 20% trichloroacetic acid solution. After vortex mixing for 1 min, 1 ml of ether was added and mixed for 2 min. After centrifuging at 10000 g for 10 min, the organic layer was transferred to another tube and the extraction procedure was repeated with another 1 ml of ether. The ether layer was evaporated to dryness under a light stream of nitrogen. The residual was dissolved by 50 ml of the mobile phase, and 20 ml was injected for HPLC analysis.
Data Analysis and Statistics The data were analyzed by analysis of variance (ANOVA) and the statistical package for the social science (SPSS 11.5) to determine the significance (pϭ0.05) of any differences observed. The data of the pharmacokinetics were calculated by the DAS 2.0 software. Peak concentration (C max ) and time of peak concentration (T max ) were obtained directly from the plasma concentration-time profiles. The area under the concentration-time curve (AUC 0-∞ ) was calculated using the trapezoidal method.
RESULTS AND DISCUSSION
Optimizing the Formulation of DTX-S-sSEDDS. Screening of Supersaturatable Promoters HPMC, PVPK30, SDS and colloidal microcrystalline cellulose (Avicel RC591) were chosen as the supersaturatable promoters in the formulation of the DTX-S-sSEDDS 1 . The in vitro dissolution of the formulations at 20 mg of drug is shown in Fig.  1 . The results showed that the dissolution of the DTX-SEDDS with supersaturatable promoters was much higher than that of the DTX-SEDDS without the presence of supersaturation promoters. The solubilizing and stabilization capability of the supersaturation promoters were in the sequence of HPMC K100ϾHPMC K15MϾHPMC K100MϾAvicelϾ SDSϾPVPK30. The dissolution of the DTX-SEDDS 1 without any supersaturation promoters decreased with time, and the system appeared supersaturatable and re-aggregated. The system of the DTX-sSEDDS 1 containing HPMC K100 did not appear supersaturatable and did not re-aggregate, and its dissolution at 3 h was 2.64 times higher than that of the DTX-SEDDS 1 without HPMC and 28.3 times as that of the DTX crude powder. However, there were no apparent differences of dissolution between 2.5% and 5% of HPMC K100 in the DTX-sSEDDS 1 , which showed that an increased quantity of HPMC was not helpful to the system of the DTXsSEDDS 1 .
The results suggested that HPMC had important effects on solubilization and the promotion of supersaturation. As reported, [23] [24] [25] [26] [27] HPMC can act as a supersaturation promoter to retard the precipitation kinetics and inhibit crystal growth. The mechanism responsible for inhibiting the crystallization of the drug explains that the HPMC might inhibit nucleation as well as crystal growth by adsorption onto the surface of the nuclei or onto the surface of crystals through hydrogen bonding.
Screening of Solid Carriers According to the method described under the item 'Solid Supersaturatable SEDDS of Docetaxel (DTX-S-sSEDDS) Prepared by Spray Drying,' different solid water soluble carriers such as mannitol, dextran 40 and lactose were used in the formulation of the DTX-S-sSEDDS 1 . The results of appearance, repose angle of the solid particles and the visual evaluation on the reconstituted emulsions are listed in Table 2 . Lactose was chosen to be the solid carrier of the DTX-S-sSEDDS 1 because it was better than mannitol and dextran 40.
Screening of Preparing Methods
The DTX-S-sSEDDS 1 and DTX-S-sSEDDS 3 had the same formulation, and were prepared by the spray drying and physical adsorption methods, respectively. Water soluble carriers such as mannitol, lactose and dextran 40 were used as solid carriers of the DTX-S-sSEDDS 1 , while commonly used excipients such as pregelatinized starch, dextrin, microcrystalline cellulose, micropowder silica gel, mannitol, lactose and, and dextran 40 were chosen as solid physical adsorbents of the DTX-SsSEDDS 3 . The multiples of adsorbent, repose angle, and reconstituted emulsions properties are compared in Table 3 . The lower the multiples of adsorbent and the angle of repose, the better the adsorbability and fluidity of the solid carriers will be, and the better the preparation method. The results showed that the multiples of the adsorbent of the same excipient such as lactose, dextran 40, or mannitol were higher in the physical adsorption method than that in the spray drying method, which would result in difficulties in the packing volume of the capsules. Therefore, the spray drying method was better than the physical adsorption method because the solution of materials was dispersed into very tiny droplets in the process of spray drying, and water in the droplets were quickly eliminated. Therefore, particles with good dispersion and solubility were obtained. Finally, the spray drying method was selected for the preparation of the DTX-SsSEDDS 1 with lactose as the solid carrier.
Droplet Size and Zeta Potential of Reconstituted Emulsions
The droplet size and zeta potential of the reconstituted emulsions from different formulations of DTX are shown in Table 4 . The results showed that the drug DTX can increase the droplet size of SMEDDS and had no effect on the zeta potential. The droplet size of the DTX-SEDDS 2 was much smaller than that of the DTX-SEDDS 1 because the total content of emulsifying excipients in the DTX-SEDDS 2 was 1.7 fold higher than that of the DTX-SEDDS 1 . However, more emulsifying excipients can reduce the safety of use at the moment of decreasing the droplet size. When HPMC was incorporated into the DTX-SEDDS 1 (i.e., DTX-sSEDDS 1 ), the droplet size of the DTX-sSEDDS 1 was even smaller than that of the DTX-SEDDS 2 . To some extent, the effect of HPMC on the diminishing droplet size of emulsion was even stronger than that of the emulsifying excipients. The droplet size of DTX-S-sSEDDS 1 prepared by the spray drying method was much smaller than that of the DTX-SEDDS 1 and slightly larger than that of the DTX-sSEDDS 1 . It was suggested that HPMC plays a role in solubilization, stabilization and diminishing the droplet size of the emulsion. HPMC as a polymeric surfactant functions as an emulsifier, protective colloid and dispersant. The stability and emulsifying function is attributed to the strong adsorption of HPMC on the particle surfaces and the enhanced steric stabilization produced by the strongly hydrated polymer chain. HPMC helps to form smaller sizes of emulsion, and prevents emulsion droplets from aggregation. 28, 29) Morphological Analysis The TEM images of the reconstituted emulsions of the DTX-SEDDS 1 , DTX-sSEDDS 1 and DTX-S-sSEDDS 1 are shown in Fig. 2 . The spherical droplets from the DTX-S-sSEDDS 1 (Fig. 2c) were much smaller than those from the liquid DTX-SEDDS 1 (Fig. 2a) and slightly larger than those from the DTX-sSEDDS 1 (Fig. 2b) . From these results, encapsulating the liquid DTX-sSEDDS 1 in lactose by spray-drying did not seem to have a remarkable effect on droplet size. Additionally, the solid DTX-S-sSEDDS 1 preserved the self-emulsification performance of the liquid DTX-SEDDS 1 .
The SEM images (Fig. 3) showed the solid DTX-SsSEDDS 1 consisting of well-separated particles. Moreover, the particle showed a satisfactory regular spherical shape with shallow dents formed during the rapid evaporation of water. When meeting with water, the dents may possibly provide a larger area of exposure to promote the dissolution and solubility of the drug. Also, the deduction can be confirmed in the in vitro dissolution tests. Lactose, as the solid carrier, has the ability to diminish the degree of spray-dried particle agglomeration. Solid State Characterization of DTX-S-sSEDDS 1 DSC curves of pure DTX powder, lactose, the physical mixture of DTX and lactose (1 : 20) and the DTX-S-sSEDDS 1 are shown in Fig. 4. In Fig. 4a , DSC measurements showed one broad endothermic peak near 117°C, a small endothermic peak at 177°C corresponding to the transconformation of the molecule, and the irregular exothermic peaks above 224°C corresponding to the decomposition of DTX. In Fig.  4b , there was a sharp endothermic peak at 150°C corresponding to the crystal water and an endothermic molten decomposition peak around 210°C that corresponds to lactose. Because the amount of lactose was far more than that of DTX, only a weak characteristics peak of DTX at approximately 177°C was observed (curve b). In Fig. 4c for the liquid DTX-SEDDS 1 , no characteristics peak of DTX was found due to SEDDS 1 forming a good solution of the drug. No other obvious peaks except the characteristics peak of lactose at approximately 210°C was found in the solid DTX-SsSEDDS 1 (curve d). It might be possible that the crystallization of DTX was inhibited in the DTX-S-sSEDDS 1 .
X-Ray powder diffractograms are shown in Fig. 5 . Pure DTX showed characteristics peaks at 5.24°, 9.94°, 10.52°, and 15.84°(curve a). Lactose showed peaks at 12.18°, 18.24°, and 19.75°(curve b). Due to the dilution by lactose, a few peaks of DTX appeared at 5.24°, 9.94°, and 15.84°in the physical mixture of DTX and lactose (curve c). No obvious peaks representing the crystals of DTX were seen for the solid DTX-S-sSEDDS 1 (curve d). Therefore, in view of the DSC curves and X-ray powder diffractograms, it can be concluded that the DTX in the solid DTX-S-sSEDDS 1 was in an amorphous or molecular dispersion state in the carrier.
Dissolution in Vitro. Effects of Formulations on Dissolution The dissolution profiles of different formulations of DTX in water at the dose of 20 mg are shown in Fig. 6 . The dissolution rate of pure DTX was very low, and all formulations of SEDDS can apparently increase the dissolution of DTX. Additionally, it can be seen that the cumulative dissolution of the other formulations of SEDDS containing HPMC are stable or slightly increased after 1 h, except the formulations of the DTX-SEDDS 1 and DTX-SEDDS 2 with- out HPMC. Due to the increased amount of emulsifying excipients in the DTX-SEDDS 2 (1000 mg) than that in the DTX-SEDDS 1 (600 mg) listed in Table 1 , the dissolution of the DTX-SEDDS 2 was decreased (3%) at 2 h and lower than that of the DTX-SEDDS 1 (23%) after 1 h. It was suggested that more emulsifying excipients in the DTX-SEDDS 2 can retard the decreasing tendency, and the higher surfactant level in formulations can possibly cause higher gastrointestinal side effects. 9, 10) Therefore, in order to improve the dissolution and stability, HPMC was involved in the formulation of the DTX-SEDDS 1 (i.e., the DTX-sSEDDS 1 ) instead of the addition of more surfactants, and it can be seen that the dissolution and stability of the DTX-sSEDDS 1 was considerably improved relative to that of the DTX-SEDDS 1 . In other words, HPMC can improve the dissolution and stability on condition of not adding more emulsifying excipients. Simultaneously, due to the good dispersion of the spray drying method, 30) the dissolution rate of the DTX-S-sSEDDS 1 at 2 h was 29.8-fold greater than that of the pure DTX, which was even higher than that of the liquid DTX-sSEDDS 1 . Although the total amount of emulsifying excipients in the DTX-SsSEDDS 1 was only 3/5 that of the conventional SEDDS (DTX-SEDDS 2 ), the percent of accumulated dissolved DTX-S-sSEDDS 1 at 2 h reached 90.96%, which was much higher than that of the DTX-SEDDS 2 (76.26%).
Effects of Different Dissolution Media on Dissolution To estimate the effects of different media on the dissolution of DTX-S-sSEDDS 1 , water, artificial gastric juice and PBS 6.8 were used as media with the given drug content of 20 mg. The results in Fig. 7 showed that good dissolution of DTX-SsSEDDS 1 was obtained in all three media without apparent differences. In other words, media had no apparent effects on dissolution.
Effects of Drug Content Given on Dissolution The dissolution profiles of the DTX-S-sSEDDS 1 with different given content of the drug are shown in Fig. 8 . The results suggested that the dissolution of the DTX-S-sSEDDS 1 decreases with the increasing content of the drug. When the given content of DTX reached 30 mg, the system appeared to be supersaturatable. However, due to the presence of HPMC, the dissolved drug in the system did not appear to re-aggregate and precipitate. It was suggested that the emulsifying excipients and HPMC had important effects on the solubilization and promotes supersaturation.
Stability Test
The results of the stability test of DTX-SsSEDDS 1 are shown in Table 5 . The comparison the appearances, visual evaluation of the reconstituted emulsions, droplet size, zeta potential, assay and dissolution of DTX-SsSEDDS 1 at 0 d showed no significant differences compared to those observed at 12 months. These observations indicated that the DTX-S-sSEDDS 1 was chemically and physically stable.
Bioavailability Study in Rats The formulations of the solid DTX-S-sSEDDS 1 , liquid DTX-SEDDS 1 and the suspension of DTX powder were administered orally to rats at a DTX dose of 10 mg/kg, and the DTX commercial injection was administered via the caudal vein at the same dose. The mean plasma DTX concentrations versus time profiles are shown in Fig. 9 . The drug was undetectable at 5 h after administration of the DTX powder. At all the indicated time points, the DTX plasma concentrations in rats treated with the DTX-S-sSEDDS 1 and liquid DTX-SEDDS 1 were significantly higher than the DTX powder suspension. The curve of the DTX-S-sSEDDS 1 was also found to be higher than that of the liquid DTX-SEDDS 1 .
The pharmacokinetic parameters of rats were summarized in Table 6 . The oral bioavailability of docetaxel from the DTX-S-sSEDDS 1 and liquid DTX-SEDDS 1 resulted in a 8.77-and 6.06-fold increase, respectively, when compared with the DTX powder suspension (0.439 mg · h/ml, 0.303 mg · h/ml vs. 0.050 mg · h/ml, pϽ0.01). Moreover, The AUC of docetaxel in the DTX-S-sSEDDS 1 increased by 45% com- pared with that of the DTX-SEDDS 1 (0.439 mg · h/ml vs. 0.303 mg · h/ml, pϽ0.01). The C max was also enhanced by 5.1-fold in the DTX-S-sSEDDS 1 compared with that of the DTX powder suspension (0.173 ng/ml vs. 0.034 ng/ml, pϽ0.01). This result is consistent with that of the in vitro release study (Fig. 6 ). The T max was relatively delayed for approximately 0.5 h in SEDDS compared to the DTX powder. In the case of the formed emulsions, it is possible that the drug needs to be released from the oil phase, thereby resulting in a delayed T max .
It is now confirmed that SEDDS can offer a remarkable improvement in the solubility, dissolution and bioavailability of DTX as other water-insoluble drugs. The spontaneous formation of an emulsion/microemulsion upon drug release presents the drug in a dissolved form with a small droplet size that provides a large interfacial surface area favored for drug absorption. Drug exposure may be enhanced by the increased solubilization in the gastrointestinal tract and enhanced accumulation in Peyer's patch for lymphatic transport of the drug. [1] [2] [3] [4] Surfactants in the formulations such as cremophor play an important role in improving the bioavailability of the drug by improving dissolution and intestinal epithelial permeability. 31, 32) However, to avoid GI side-effects caused by high surfactant levels in conventional SEDDS formulations, the supersaturatable self-emulsifying drug delivery system (sSEDDS) of DTX was designed. This sSEDDS contains a reduced amount of surfactant and a supersaturation promoter (HPMC) to retard the precipitation of DTX by generating and maintaining a supersaturated in vivo state. As shown in Table 4 and Fig. 6 , due to the existence of HPMC, the particle diameter of the DTX-sSEDDS 1 was only one-fourth that of the DTX-SEDDS 1 without the presence of HPMC. Also, the percent of accumulated dissolution of the DTX-sSEDDS 1 at 2 h increased by 13%, although the total amount of emulsifying excipients in DTX-sSEDDS 1 was only 3/5 that of the conventional SEDDS (DTX-SEDDS 2 ). In order to further improve the stability of SEDDS, incorporation of a supersaturatable liquid self-emulsifying formulation into a solid dosage form may combine the advantages of the solid SEDDS (S-SEDDS) with those of the supersaturatable SEDDS (sSEDDS). As shown in Fig. 6 and Table 6 , the dissolution of the DTX-S-sSEDDS 1 was slightly higher than that of the DTX-sSEDDS 1 because of the good dispersion of the solid carrier. Additionally, the AUC of the DTX-SsSEDDS 1 increased by nearly 8.77 and 1.45 fold as compared with those of the DTX crude powder and DTX-SEDDS 1 .
CONCLUSION
In the present investigation, the solid supersaturatable SMEDDS of docetaxel (DTX-S-sSEDDS) was prepared by spray drying, using lactose as the solid carrier and HPMC as the supersaturation promoter. Compared to the conventional liquid DTX-SEDDS, the DTX-S-sSEDDS has advantages in solubility, dissolution, bioavailability, stability and safety. Thus, the solid supersaturatable SMEDDS technology provides an effective approach for improving the dissolution and bioavailability of docetaxel with a low level of emulsifying excipients as well as good stabilization and safety.
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